[Treatment of metastasizing breast cancer with aminoglutethimide].
Aminoglutethimide was applied for treatment of 10 patients (8 postmenopausal, 2 ovariectomized) with metastasizing breast cancer. The patients were extensively pretreated with cytostatic and hormonal measurements and already completely resistant to these therapies. Using aminoglutethimide (500-1000 mg daily) plus additional substitution with 20-40 mg hydrocortisone one complete and three partial remissions could be achieved. Stabilization was observed in 3 cases. The duration of remission varied between 4-8 months in 3 cases and lasted one month in a further patient.
D000368:Aged; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D001259:Ataxia / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D004351:Drug Resistance; D004958:Estradiol / Q000097:blood; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis
D002272:Carcinoembryonic Antigen; D000616:Aminoglutethimide; D004958:Estradiol; D006854:Hydrocortisone
Die Behandlung des metastasierenden Mammakarzinoms mit Aminoglutethimid.